Spyre Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Spyre Therapeutics has a total shareholder equity of $327.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $421.1M and $93.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$414.23m |
| Equity | US$327.39m |
| Total liabilities | US$93.70m |
| Total assets | US$421.09m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 3920's short term assets ($421.1M) exceed its short term liabilities ($57.5M).
Long Term Liabilities: 3920's short term assets ($421.1M) exceed its long term liabilities ($36.2M).
Debt to Equity History and Analysis
Debt Level: 3920 is debt free.
Reducing Debt: 3920 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3920 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 3920 has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 15.3% each year.